Selexis, ImmuNext Announces Cell Line License Agreement
Complete the form below to unlock access to ALL audio articles.
Selexis SA has announced the signing of a commercial license agreement that provides ImmuNext Inc with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™ to advance the development of ImmuNext’s anti-CD40 ligand (CD40L) antibody. ImmuNext is developing this antibody for treatment of chronic autoimmune disorders with high unmet medical need, such as lupus, inflammatory bowel disease and multiple sclerosis.
CD40L (also called CD154) is a highly validated, superlative therapeutic target in autoimmunity and graft rejection. CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF family of molecules. It binds to CD40 on antigen-presenting cells, which leads to many effects depending on the target cell type.
“We are pleased to expand our relationship with ImmuNext, which began out of a necessity to rapidly and predictably develop a high productivity cell line that would meet ImmuNext’s demand projections in the event of a successful clinical development and commercial launch of their anti-CD40L antibody,” said Yemi Onakunle, PhD, vice president, licensing and business development, Selexis SA.
“ImmuNext’s development program received a $1.8M Small Business Innovation and Research (SBIR) Phase 2B award from the National Institutes of Health earlier this year for pre-clinical development of its proprietary anti-CD40L antibody. The Selexis team is proud to have played a small role in helping the company to advance its research and secure such an important award that will help to meet unmet medical need.”
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
